The American Journal of Medicine
Volume 120, Issue 8, Supplement 1 , Pages S14-S22 , August 2007

Preventing Chronic Obstructive Pulmonary Disease: What Is Known and What Needs to Be Done to Make a Difference to the Patient?

  • Robert A. Wise, MD

      Affiliations

    • Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Robert A. Wise, MD, Johns Hopkins University School of Medicine, Division of Pulmonary and Critical Care Medicine at the JHU Asthma and Allergy Center, 5501 Hopkins Bay View Circle, Room 4B.74, Baltimore, MD 21224.
    • ,
  • Donald P. Tashkin, MD

      Affiliations

    • Division of Pulmonary, Critical Care Medicine, and Hospitalists, David Geffen School of Medicine at UCLA, University of California–Los Angeles, Los Angeles, California, USA.

References 

  1. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2006. http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed April 27, 2007.
  2. National Heart, Lung, and Blood Institute, National Institutes of Health. Chronic obstructive pulmonary disease data fact sheet. Available at: http://www.nhlbi.nih.gov/health/public/lung/other/copd_fact.htm. Accessed June 23, 2006.
  3. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA. 2005;294:1255–1259
  4. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343:269–280
  5. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–2653
  6. National Heart, Lung, and Blood InstituteNational Institutes of Health. Chronic Obstructive Lung Disease: Summary of the Health Consequences of Smoking. A Report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood Institute; 1984;
  7. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900
  8. Mahadeva R, Lomas DA. Genetics and respiratory disease. 2. α1-Antitrypsin deficiency, cirrhosis and emphysema. Thorax. 1998;53:501–505
  9. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med. 2006;119(suppl 1):S21–S31
  10. Celli BR, MacNee W ATS/ERS Task Force Committee Members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946
  11. American Thoracic Society. American Thoracic Society statement: occupational contribution to the burden of airway disease. Am J Respir Crit Care Med. 2003;167:787–797
  12. Agustí AGN. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:367–370
  13. Wouters EFM, Creutzberg EC, Schols AM. Systemic effects in COPD. Chest. 2002;121(suppl):127S–130S
  14. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–2107
  15. van Manen JGE, Bindels PJE, Dekker FW, et al. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol. 2003;56:1177–1184
  16. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152(pt 2):S77–S120
  17. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(suppl):121S–126S
  18. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance—United States, 1971-2000. MMWR Surveill Summ. 2002;51:1–16
  19. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax. 1996;51:164–168
  20. Dickinson JA, Meaker M, Searle M, Ratcliffe G. Screening older patients for obstructive airways disease in a semi-rural practice. Thorax. 1999;54:501–505
  21. Van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ. 2002;324:1370
  22. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology. 2003;8:504–508
  23. Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest. 2004;125:1394–1399
  24. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2006. Available at: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989. Accessed January 31, 2007.
  25. National Collaborating Centre for Chronic Conditions, on behalf of the National Institute for Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. Clinical Guideline No. 12. London: National Institute for Clinical Excellence, National Health Service, February 2004. Available at: http://www.nice.org.uk/cg012NICEguideline. Accessed October 12, 2006.
  26. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease—2003. Can Respir J. 2003;10(suppl A):11A–65A
  27. Global Initiative for Chronic Obstructive Lung Disease [GOLD]. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: NHLBI/WHO Workshop Report. National Heart, Lung, and Blood Institute, National Institutes of Health, US Dept of Health and Human Services; 2001;Available at: http://www.goldcopd.com/Guidelineitem.asp?l1=2&l2=1&intId=1151. Accessed April 4, 2006
  28. Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ. Misdiagnosis of COPD and asthma in primary care patients 40 years of age and over. J Asthma. 2006;43:75–80
  29. Wilt TJ, Niewoehner D, Kim C-B, et al. Use of Spirometry for Case Finding, Diagnosis, and Management of Chronic Obstructive Pulmonary Disease (COPD). Evidence Report/Technology Assessment: Number 121. Rockville, MD: Agency for Healthcare Research and Quality, September 2005. AHRQ Publication No. 05-E017-2. Available at: http://www.ahrq.gov/clinic/epcsums/spirosum.htm. Accessed August 21, 2006.
  30. Raghunath AS, Innes A, Norfolk L, et al. Difficulties in the interpretation of lung function tests in the diagnosis of asthma and chronic obstructive pulmonary disease. J Asthma. 2006;43:657–660
  31. Petty TL. Benefits of and barriers to the widespread use of spirometry. Curr Opin Pulm Med. 2005;11:115–120
  32. American Medical Association. CPT© Plus! A Comprehensive Guide to Current Procedural Terminology. 2003 ed.. Los Angeles: Practice Management Information Corporation; 2002;
  33. Emphysema and PFTs. Med Econ. 2003;80:19;[coding consult]
  34. Lee TA, Bartle B, Weiss KB. Spirometry use in clinical practice following diagnosis of COPD. Chest. 2006;129:1509–1515
  35. Pierce R, Johns DP. Spirometry: The Measurement and Interpretation of Ventilatory Function in Clinical Practice. Available at: http://www.nationalasthma.org.au/html/management/spiro_book/index.asp. Accessed October 11, 2006.
  36. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–338
  37. Schermer TR, Jacobs JE, Chavannes NH, et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax. 2003;58:861–866
  38. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1977;1:1645–1648[review]
  39. Scanlon PD, Connett JE, Waller LA, et al. Lung Health Study Research Group Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the Lung Health Study. Am J Respir Crit Care Med. 2000;161:381–390
  40. Anthonisen NR, Connett JE, Murray RP Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002;166:675–679
  41. Rennard SI, Daughton DM. Smoking cessation. Chest. 2000;117(suppl):360S–364S
  42. Fiore MC, Bailey WC, Cohen SJ, et al, for the Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence (revised 2000) [Health Services/Technology Assessment Text Web site]. Rockville, MD: US Dept of Health and Human Services, Public Health Service, June 2000. Clinical Practice Guideline No. 18 (updated). Available at: http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat2.chapter.7644. Accessed December 8, 2006.
  43. Zhu S-H, Anderson CM, Tedeschi GJ, et al. Evidence of real-world effectiveness of a telephone quitline for smokers. N Engl J Med. 2002;347:1087–1093
  44. Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–1202
  45. Jorenby DE, Hays JT, Rigotti NA, et al. Varenicline Phase 3 Study Group Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56–63
  46. US Department of Health and Human Services. Smoking Cessation: Clinical Practice Guidelines. Rockville, MD: US Dept of Health and Human Services; 1996;AHCPR Publication No. 96-0692
  47. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685–691
  48. Tashkin DP, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357:1571–1575
  49. Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47–55
  50. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(1):CD002733
  51. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61:189–195

PII: S0002-9343(07)00404-4

doi: 10.1016/j.amjmed.2007.04.008

The American Journal of Medicine
Volume 120, Issue 8, Supplement 1 , Pages S14-S22 , August 2007

Article Tools

* Image Usage & Resolution